Principal Scientist CVMD - (Gaithersburg, MD)

Organization
MedImmune
Job Location
Gaithersburg, MD
Job Description

 

If you're inspired by the possibilities of science to change lives and you thrive when making brave decisions - join us. 
MedImmune is the worldwide biologics research and development arm of AstraZeneca. Here, you'll have the opportunity to make a difference in people's lives every day. As one of the world's premier biotechnology companies, our mission is centered on delivering life-changing products that advance world health, and help fight and cure disease. As a Principal Scientist in Gaithersburg, MD, you'll play a pivotal role in channeling our scientific capabilities to make a positive impact on changing patients' lives. 
We're constantly pushing the boundaries of science to deliver life-changing medicines to patients, with a passion for discovery and a pipeline to show for it. We're pioneering innovative research and exploring novel pathways across key therapeutic areas including oncology, respiratory, inflammation and autoimmunity, cardiovascular and metabolic disease, and infection and vaccines. And we're industry-leading in immunology, protein engineering and translational science. We offer a unique and strong collaborative network as part of the AstraZeneca family, as together we explore synergies between small and large molecules. 
MedImmune has a dynamic environment that fosters collaboration and innovation. We attract top minds, and we nurture and build top talent.

Requirements: 
Main Duties and Responsibilities 
Those who join MedImmune feel a sense of ownership about their future. They thrive with a recognized leader in the biotechnology ...cont.

A part of the proposed tax bill in the US could make tuition waivers taxable, Vox reports.

The New York Times reports that only a subset of STEM worker are in demand.

US News & World Report says students pursuing STEM degrees should consider what they are getting into.

New study finds bias against female lecturers among student course evaluations, the Economist reports.